Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what ...

In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

TD Cowen initiated coverage of Repligen (RGEN) with a Buy rating and $200 price target Repligen is well positioned for “industry-leading” ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Consumer staples are known for their stability during market volatility, as demand for essential goods remains consistent. Exclusive content, detailed data sets, and best-in-class trade insights ...